UBX-103: potentially first in class A... - Advanced Prostate...

Advanced Prostate Cancer

21,581 members27,011 posts

UBX-103: potentially first in class AR degrader

Maxone73 profile image
1 Reply

keep an eye on this (help me I am running out of eyes!) an AR degrader really aims at destroying AR receptors, the idea is that when a second generation arsi is no longer working (Enza, Daro,…) you still have the option to use this new drug for metastatic prostate cancer

biospace.com/article/releas...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
1 Reply
j-o-h-n profile image
j-o-h-n

Use Y's

Good Luck, Good Health and Good Humor.

j-o-h-n

Not what you're looking for?

You may also like...

Dangers of AR degradation through ARV-110 etc?

on the thread on loss and revival of androgen receptor signaling through the over repression of the...

Novel AR-Targeted Therapies for mHSPC: Which One to Choose

herapies-for-metastatic-hormone-sensitive-prostate-cancer-which-one-to-choose A comment stood out...

PROTAC -- new class of drug - first trial for prostate cancer

mid-2019, will include 28–36 men with metastatic prostate cancer and will last around 9 months,...

AR-V7 - CTC's - Risk of Death

benefit-for-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html

Can melatonin control AR amplification and therefore help mCRPC drugs work better and longer?

in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant...